1/9
Vocabulary flashcards detailing the clinical indications, mechanism of action, dosing, safety considerations, and monitoring requirements for methimazole.
Indications for Methimazole
Mechanism of Action (MOA) of Methimazole
Inhibits thyroid peroxidase, blocking the oxidation of iodide, iodination of tyrosine (MIT/DIT), and coupling into T3/T4.
Time to Euthyroid (Methimazole)
Takes 3–12weeks to reach euthyroid because it does not destroy hormone that has already been synthesized.
Methimazole vs. PTU on Peripheral Conversion
PTU blocks peripheral T4→T3 conversion, whereas methimazole does not.
Methimazole Half-Life and Frequency
Half-life of 6–13h, allowing for once-daily dosing.
Methimazole Dosing Regimen
Initial dose of 30–40mg/day, followed by a maintenance dose of 5–15mg/day, administered for 1–2years.
Agranulocytosis with Methimazole
A rare adverse effect (∼3/10,000) typically occurring in the first 2months; heralded by fever or sore throat, requiring immediate discontinuation of the drug and checking a CBC.
Methimazole in Pregnancy
Teratogenic in the 1st trimester (during which PTU is used instead); methimazole is used during the 2nd and 3rd trimesters.
Methimazole Breastfeeding Threshold
Considered acceptable while breastfeeding up to a dose of 20mg/day.
Methimazole Monitoring Requirements
CBC with differential and LFTs at baseline, alongside free T4/T3.